SIMCERE PHARMA (02096) announced that on January 26, 2026, its subsidiary, Simcere Pharmaceutical Co., Ltd. (Jiangsu Simcere), entered into an exclusive licensing agreement with Boehringer Ingelheim. Under the terms of the agreement, Boehringer Ingelheim will obtain the global exclusive rights, outside of Greater China, for SIM0709, a TL1A/IL-23p19 bispecific antibody intended for the treatment of inflammatory bowel disease. This licensing deal further validates the innovation and leading position of the Group's autoimmune disease research and development platform. According to the agreement terms, the Group is entitled to receive an upfront payment of 42 million euros, along with potential milestone payments of up to 1.016 billion euros, contingent upon achieving specific development, regulatory approval, and commercial milestones. Furthermore, the Group is also entitled to receive tiered royalties on net sales generated outside Greater China. SIM0709 is a long-acting, humanized bispecific antibody independently developed by the Group based on its proprietary multispecific antibody platform. SIM0709 is designed to simultaneously target Tumor Necrosis Factor Ligand Superfamily Member 15 (TL1A) and Interleukin-23 (IL-23), thereby blocking two core pathways involved in the onset and progression of inflammatory bowel disease. In both in vitro primary cell experiments and in vivo animal studies, SIM0709 has demonstrated superior synergistic efficacy, even outperforming the combined use of the two individual monoclonal antibodies.